Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
about
Oncolytic virus therapy: A new era of cancer treatment at dawnClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityFrom kinetics and cellular cooperations to cancer immunotherapiesMoving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic virusesEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesOncolytic adenovirus-mediated therapy for prostate cancerHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsSickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In VivoPrime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapyPresage of oncolytic virotherapy for oral cancer with herpes simplex virus.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesCooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma ModelsMurine Tumor Models for Oncolytic Rhabdo-Virotherapy.Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic AdenocarcinomaPD-1 blockade enhances the vaccination-induced immune response in gliomaPhase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.Targeting Melanoma with Cancer-Killing Viruses.Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.Oncolytic virotherapy for urological cancers.Metabolic regulation of immune responses: therapeutic opportunities.Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.Systemic virotherapy for multiple myeloma.NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.Oncolytic viruses on the cusp of success?: proceedings of the 9th International Conference on Oncolytic Virus Therapeutics.Review: Oncolytic virotherapy, updates and future directions.TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.
P2860
Q26739714-50754DD9-D5D5-4208-BBC7-42C293012DE8Q26750568-09FF517C-361E-4D23-ADB3-9ECC8EE55E47Q26750783-8C819B9E-5B98-4948-B87C-F37F66C0E01AQ26752807-E2ABCD7F-7CF9-48F2-81F0-18E275A9D201Q26775030-D74634A2-47D5-4381-812A-D0CDB1BB8362Q26775033-96F446A9-64B4-417E-9B95-1D7ECCFAB8F8Q26863779-EF454C5D-D696-4BF2-BB04-41707CF4B884Q27004796-AA6D6893-607E-452F-AA8E-0A505C731E68Q28086999-EC50599C-7C36-492B-A1DD-1942CAEDB878Q28596621-DFBC4EE2-DA16-492B-B066-1426FA3FE4C8Q33551626-063B7ED0-C034-4458-8B25-AF40A13399F7Q33603748-C6A7A0CD-3764-4D3E-BFD5-B151DD79DC8AQ33679505-8C1FFE6E-7866-4AD0-A391-179930F220E6Q33725706-8FF76156-58E7-454A-87FD-23C8BC17D870Q36751597-70F7D0A0-1506-47FC-BFCC-256C5221F5A8Q37043514-EE4C93DF-5D7F-4167-8952-A84019F1B8BCQ37109193-8DBBE0D3-184F-4199-B830-6D828B52A9F6Q37256174-4325A707-423A-4F4C-9783-3D3739CF421FQ37347236-A0106E0B-3868-4752-BC00-7DAF55F7964CQ37417271-A871ECA4-F1F6-4E46-9519-1FCF227B532BQ37651860-BBD9E2BF-1D69-4801-BEC0-04AE464726E4Q37736296-F2D28739-5208-4F82-A547-F91F993D3893Q38676416-E1661FB5-C6D8-4458-82A7-12CEA3A852BEQ38746023-5BA3A6E0-B947-430A-97A7-7777A7E4594DQ38781322-025F69CE-8506-461B-ABD6-37563D870AB9Q38790788-BEDF59FB-7963-4284-97EE-F0A214CC3E6BQ38842126-EEECE3E3-A249-4F6D-A640-B7152B30FD83Q38850162-63DE21C6-3523-4AA0-AF30-5F98349F3C62Q38941936-4479AC7A-E610-4B6F-9177-2DCD6EDAC7A5Q39387174-D4B35CAB-157A-4F60-9954-E471CCE7E32EQ40082476-5D2AB0E8-D24E-4DFB-AE4F-5C420342D33DQ40087770-025A01AA-9ECC-4A4F-B52A-0AB6249F2AE0Q40115977-B5B2272A-234E-4BB4-B9B4-FBCA19509AD8Q40294106-3F90E3FC-49C0-4415-8148-C098492246B4Q40529135-6C8192D4-E7A8-4BFF-A4BD-925FABAFF1E0Q46265659-4203232B-29E5-48FB-9F13-7539913C0E96Q47160989-7EF09595-35BC-4B2D-87CF-596481993745Q50020811-DE99A0D5-685F-4B18-B25A-BC32BE7402A6Q52674215-D14672EC-65D8-4CFE-BAA2-F5D04B315ABFQ53706001-74F3B9EB-A7FD-44A1-A705-09FC777E58AE
P2860
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@ast
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en-gb
type
label
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@ast
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en-gb
prefLabel
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@ast
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en-gb
P2093
P2860
P356
P1154
2-s2.0-84957845897
P1433
P1476
Combination Therapy With Reovi ...... and Adaptive Immune Responses
@en
P2093
Christopher Parrish
Hardev Pandha
Jill Thompson
Karishma Rajani
Kevin G Shim
Kevin Harrington
Matt Coffey
Richard Vile
Rosa-Maria Diaz
P2860
P304
P356
10.1038/MT.2015.156
P50
P5530
P577
2015-08-27T00:00:00Z
P5875
P6179
1028425793